Spain Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is intensifying its commitment to the country with a total investment of EUR 1.3 billion its new global R&D hub in…
Spain Having forged a solid position in clinical research in 2020 and 2021 when it became the fourth nation in the world and the first in Europe for studies conducted around COVID-19, Spain has continued consolidating its status as a leading clinical trials hub and registered over 900 trials in 2022,…
Europe The European Union’s just-released and first essential medicines list is the latest in a series of measures designed to limit the bloc’s reliance on countries outside its borders and avoid drug shortages. As Elisabeth Stampa of generic and biosimilar lobby group Medicines for Europe recently explained to PharmaBoardroom, this is…
Spain A roundup of the latest news from Spanish pharma, including Almirall’s licensing deal with EpimAb Biotherapeutics; the opening of Insud Pharma’s oligonucleotides centre in India, and Esteve Química’s new FDA-cleared manufacturing site. Almirall licenses bispecific platform in $210m EpimAb deal (BioProcess International) EpimAb Biotherapeutics has out-licensed the rights for…
Spain Spanish mid-cap Esteve is selling a 26 percent stake in the company to German private investment firm Lubea, a move it says will supply the necessary funds to further pursue its redefined company strategy while stepping up growth and allowing for additional international expansion. Expansion: Products and Geographies Esteve, a…
Spain The latest news from Spanish pharmaceuticals and healthcare, including national champion Esteve’s decision to sell of a quarter of its stock to German private investment firm Lubea; news of pharma’s increased weighting in Spain’s exports for 2022; and why – bolstered by EU recovery funds – the country has a…
Spain A roundup of the latest news from Spanish pharma, including Almirall’s earnings forecast for 2023; stock price rise and layoffs at Grifols; PharmaMar’s first European approval for its lurbinectedin treatment of metastatic Small Cell Lung Cancer and Esteve’s launch of the first inhaled rescue treatment for Parkinson’s patients. Spain’s…
Greece The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic and social impact of the COVID-19 pandemic, but for many biopharma industry leaders they also present an opportunity to tackle…
Spain What major regulatory trends are emerging in Europe and in Spain? As one of the founding partners of a law firm focused uniquely on the life sciences industry, Faus & Moliner Abogados, Jordi Faus has been confronting the industry’s unique legal issues for over 25 years. In a recent PharmaBoardroom…
Spain Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate managers, and the heads of some of the country’s leading domestic firms. These interviewees’ insights are catalogued in the downloadable…
Spain The outbreak of the COVID-19 pandemic put an end to more than five years of economic growth in Spain. But the country was not alone. Due to strict containment measures, the Europe’s economy went into the greatest recession since the Second World War during the first half of 2020. To…
Spain After decades of investment, Catalonia has secured its healthcare and life sciences hub status, accounting for more than half of Spain’s pharma exports and with more clinical trials than any other region. The birthplace of many of the country’s pharma success stories, Catalonia boasts a strong scientific output by European…
See our Cookie Privacy Policy Here